Pet health and wellness company PetIQ (PETQ) reported a 15.5% jump in sales, while net loss widened to $3.39 million. The increased net loss was largely due to the one-time non-cash tax expense of $3.4 million, or $0.16 per diluted share for the revaluation of deferred tax assets, and a provisional tax expense of $0.2 million.
Gross profit for the quarter increased 38.1% year-over-year, driven by improved net sales which created improved sales mix of categories that were more profitable and procurement improvements.
PetIQ also announced that it has reached an agreement to open 20 veterinarian clinics within Walmart stores. These clinics will be opened between March and the end of the second quarter of 2018.
Outlook
The company expects full year 2018 net sales in the range of $450 million to $500 million, up 69% to 87% year-over-year. Adjusted EBITDA is expected in the range of $40 million to $45 million, up 79% to 102% year-over-year.
Most Popular
Context Therapeutics: Another clinical-stage oncology research firm to go public soon
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
